Amalia Gastaldelli (Italy)
Institute of Clinical Physiology, CNR
Cardiometabolic Risk Unit
She is the Research Director of the Cardiometabolic Risk UNIT and of Mass Spectrometry Laboratory at CNR-IFC in Pisa Italy; also appointed as adjunct Professor at the Diabetes Division of the University of Texas Health Science Centre (UT Health) in San Antonio, Texas, USA and associate researcher in Sant'Anna School of Advanced Studies in Pisa. She has more than 25 year experience in leading national and international scientific projects investigating metabolic diseases including obesity, non alcoholic fatty liver disease (NAFLD) and type 2 diabetes. These include alterations in glucose and lipid metabolism, insulin resistance and ectopic fat accumulation collaborating with many institutions in Europe and United States. She is currently the chair of the EASD NAFLD Study Group, which provides a joint forum for diabetologists and hepatologists to explore the diagnosis, pathogenesis and treatment of NAFLD and NASH, and the chair of the EASD EGIR Study Group which focuses on insulin action and secretion. She was part of the EASL-EASD-EASO committee for the writing of the “Clinical Practice Guidelines for the management of NAFLD” (2016). She more than 300 publications as articles in international journals and book chapters with a global H index of 87 and more than 30,000 citations.

Presenter of 2 Presentations

 Conference Calendar

Tirzepatide actions on ectopic fat accumulation: results of MRI addendum of SURPASS-3

Session Name
0590 - PARALLEL SESSION - DUAL AGONIST (ID 39)
Session Type
Parallel Session
Date
Fri, 29.04.2022
Session Time
16:40 - 18:00
Room
Hall 115
Presenter
Lecture Time
16:55 - 17:10

Abstract

Abstract Body

ABSTRACT

Background and aims: The effect of tirzepatide, a novel dual GIP/GLP-1 receptor agonist, vs insulin degludec (IDeg) on liver fat content (LFC) and visceral and abdominal subcutaneous adipose tissue (VAT and ASAT) was assessed with MRI techniques in a subpopulation of participants in the SURPASS-3 trial.

Methods: Insulin-naive participants with type 2 diabetes and Fatty Liver Index ≥60 had an MRI scan performed before randomisation (1:1:1:1) to once-weekly tirzepatide (5, 10, 15 mg) or once-daily IDeg as add-on to metformin with/without sodium-glucose co-transporter-2 inhibitors (SGLT-2i). The primary outcome was the change from baseline in LFC at Week 52 using pooled data from tirzepatide 10/15-mg arms vs IDeg. Secondary outcomes compared the individual tirzepatide doses vs IDeg at Week 52 for LFC, VAT and ASAT volumes; proportions of participants achieving LFC targets.

Results: A total of 296 participants had evaluable MRI data during the study (mean baseline age, 56.2 years; diabetes duration, 8.3 years; HbA1c, 8.2%; weight, 94.4 kg; BMI, 33.5 kg/m2; 30% on SGLT-2i). The reduction from baseline in LFC at Week 52 was significantly greater for the pooled tirzepatide 10/15-mg arms vs IDeg arm and for all individual tirzepatide doses vs IDeg. The proportions of participants achieving LFC targets were significantly greater in each tirzepatide arm vs IDeg arm. All tirzepatide doses reduced VAT and ASAT volumes at Week 52 while IDeg increased both. The results were similar regardless of the concomitant use of SGLT-2i.

Conclusions: Tirzepatide demonstrated clinically meaningful reductions in LFC and VAT and ASAT volumes compared to IDeg in this SURPASS-3 substudy.

table abstract.jpg

Hide

EFFECT OF TIRZEPATIDE VERSUS INSULIN DEGLUDEC ON LIVER FAT CONTENT AND ABDOMINAL ADIPOSE TISSUE IN PATIENTS WITH TYPE 2 DIABETES (SURPASS-3 MRI)

Session Name
0210 - VIRTUAL ORAL PRESENTATIONS SESSION 1 (ID 78)
Session Type
Virtual Oral Presentations Session
Date
Thu, 28.04.2022
Session Time
13:00 - 14:30
Room
Virtual Hall 1.1
Presenter
Lecture Time
13:56 - 14:04

Abstract

Background and Aims

The effect of tirzepatide, a novel dual GIP/GLP-1 receptor agonist, vs insulin degludec (IDeg) on liver fat content (LFC) and visceral and abdominal subcutaneous adipose tissue (VAT and ASAT) was assessed with MRI techniques in a subpopulation of participants in the SURPASS-3 trial.

Methods

Insulin-naive participants with type 2 diabetes and Fatty Liver Index ≥60 had an MRI scan performed before randomisation (1:1:1:1) to once-weekly tirzepatide (5, 10, 15 mg) or once-daily IDeg as add-on to metformin with/without sodium-glucose co-transporter-2 inhibitors (SGLT-2i). The primary outcome was the change from baseline in LFC at Week 52 using pooled data from tirzepatide 10/15-mg arms vs IDeg. Secondary outcomes compared the individual tirzepatide doses vs IDeg at Week 52 for LFC, VAT and ASAT volumes; proportions of participants achieving LFC targets.

Results

A total of 296 participants had evaluable MRI data during the study (mean baseline age, 56.2 years; diabetes duration, 8.3 years; HbA1c, 8.2%; weight, 94.4 kg; BMI, 33.5 kg/m2; 30% on SGLT-2i). The reduction from baseline in LFC at Week 52 was significantly greater for the pooled tirzepatide 10/15-mg arms vs IDeg arm and for all individual tirzepatide doses vs IDeg. The proportions of participants achieving LFC targets were significantly greater in each tirzepatide arm vs IDeg arm. All tirzepatide doses reduced VAT and ASAT volumes at Week 52 while IDeg increased both. The results were similar regardless of the concomitant use of SGLT-2i.

attd table.png

Conclusions

Tirzepatide demonstrated clinically meaningful reductions in LFC and VAT and ASAT volumes compared to IDeg in this SURPASS-3 substudy.

Hide